Skip to main content
SpringerLink
Log in

De nieuwe ADA/EASD-consensus type 2 diabetes en wat u daarvan moet weten

  • Opinie
  • Published:
Nederlands Tijdschrift voor Diabetologie Aims and scope

Samenvatting

De behandeling van type 2 diabetes wordt meer en meer complex. Enerzijds is dat vanwege de multimorbiditeit die patiënten met type 2 diabetes zo kenmerkt. Het gaat dan niet alleen om type 2 diabetes met eventuele complicaties, maar ook problemen die zich voordoen bij artrose, reumatische klachten, COPD, hartfalen en gastro-intestinale.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figuur 1.

Referenties

  1. Wolffenbuttel BHR, Vliet S van, Knols AJ, Slits WL, Sels JP, Nieuwenhuijzen Kruseman AC. Clinical characteristics and management of diabetic patients residing in a nursing home. Diabetes Res Clin Pract 1991;13:199–206.

    Article  CAS  PubMed  Google Scholar 

  2. Ekundayo OJ, Muchimba M, Aban IB, Ritchie C, Campbell RC, Ahmed A. Multimorbidity due to diabetes mellitus and chronic kidney disease and outcomes in chronic heart failure. Am J Cardiol 2009;103:88–92.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Baal PH van, Engelfriet PM, Boshuizen HC, Kassteele J van de, Schellevis FG, Hoogenveen RT. Co-occurrence of diabetes, myocardial infarction, stroke, and cancer: quantifying age patterns in the Dutch population using health survey data. Popul Health Metr 2011;9:5–1.

    Article  Google Scholar 

  4. Findley P, Shen C, Sambamoorthi U. Multimorbidity and persistent depression among veterans with diabetes, heart disease, and hypertension. Health Soc Work 2011;36:109–19.

    Article  PubMed  Google Scholar 

  5. Aroda VR, Henry RR, Han J et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther 2012;34:1247–58.

    Article  CAS  PubMed  Google Scholar 

  6. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360–72.

    Article  CAS  PubMed  Google Scholar 

  7. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963–72.

    Article  PubMed  Google Scholar 

  8. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–79.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. UK Prospective Diabetes Study Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–53.

    Article  Google Scholar 

  10. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–65.

    Article  Google Scholar 

  11. Riddle MC. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 2010;122:844–6.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129–39.

    Article  CAS  PubMed  Google Scholar 

  13. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9.

  14. The HOPE Study Investigators. Effects of an angiotensinconverting -enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145–53.

    Article  Google Scholar 

  15. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253–9.

    Article  Google Scholar 

  16. Gerstein HC, Yusuf S, Holman R, Bosch J, Pogue J. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004;47:1519–27.

    Article  CAS  PubMed  Google Scholar 

  17. Mancia G. Effects of intensive blood pressure control in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 2010;122:847–9.

    Article  PubMed  Google Scholar 

  18. Feinstein AR. The persistent clinical failures and fallacies of the UGDP study. Clin Pharmacol Ther 1976;19:78–93.

    CAS  PubMed  Google Scholar 

  19. Kilo C, Miller JP, Williamson JR. The crux of the UGDP: spurious results and biologically inappropriate data analysis. Diabetologia 1980;18:179–85.

    Article  CAS  PubMed  Google Scholar 

  20. Fisman EZ, Tenenbaum A, Boyko V et al. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 2001;24:151–8.

    Article  CAS  PubMed  Google Scholar 

  21. Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? a meta-analysis of observational studies. Diabetes Care 2008;31:1672–8.

    Article  PubMed Central  PubMed  Google Scholar 

  22. Horsdal HT, Sondergaard F, Johnsen SP, Rungby J. Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study. Pharmacoepidemiol Drug Saf 2011;20:331–7.

    Article  CAS  PubMed  Google Scholar 

  23. Sehra D, Sehra S, Sehra ST. Sulfonylureas: do we need to introspect safety again? Expert Opin Drug Saf 2011;10:851–61.

    Article  CAS  PubMed  Google Scholar 

  24. Holman RR, Steemson J, Darling P, Reeves WG, Turner RC. Human ultralente insulin. Br Med J (Clin Res Ed) 1984;288:665–8.

    Article  CAS  Google Scholar 

  25. Scholtz HE, Pretorius SG, Wessels DH, Becker RH. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 2005;48:1988–1995.

    Article  CAS  PubMed  Google Scholar 

  26. Meyer BH, Muller FO, Luus HG, Eckert HG. Bioavailability of three formulations of glibenclamide. S Afr Med J 1989;76:146–7.

    CAS  PubMed  Google Scholar 

  27. Cui HD, Jiang WD, Zhu XX, Guo Y, Karras HO. Pharmacokinetics and relative bioavailability of tablet of micronized glibenclamide in 4 Chinese healthy men. Zhongguo Yao Li Xue Bao 1993;14:193–7.

    CAS  PubMed  Google Scholar 

  28. Fisman EZ, Tenenbaum A, Benderly M, Goldbourt U, Behar S, Motro M. Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up. Cardiology 1999;91:195–202.

    Article  CAS  PubMed  Google Scholar 

  29. Monami M. Metformin may not reduce cardiovascular risk or all-cause mortality. Evid Based Med 2012.

  30. Boussageon R, Supper I, Bejan-Angoulvant T et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med 2012;9:e100120–4.

    Article  Google Scholar 

  31. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22.

  32. Hemmingsen B, Christensen LL, Wetterslev J et al. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. BMJ 2012;344:e177–1.

    Google Scholar 

  33. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457–71.

    Article  CAS  PubMed  Google Scholar 

  34. Nissen SE, Nicholls SJ, Wolski K et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561–73.

    Article  CAS  PubMed  Google Scholar 

  35. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180–8.

    Article  CAS  PubMed  Google Scholar 

  36. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170:1191–201.

    Article  CAS  PubMed  Google Scholar 

  37. Kermode-Scott B. Meta-analysis confirms raised risk of bladder cancer from pioglitazone. BMJ 2012;345:e454–1.

    Google Scholar 

  38. Mamtani R, Haynes K, Bilker WB et al. Association Between Longer Therapy With Thiazolidinediones and Risk of Bladder Cancer: A Cohort Study. J Natl Cancer Inst 2012.

  39. Wolffenbuttel BHR, Haeften TW van. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM). Drugs 1995;50:263–88.

    Article  CAS  PubMed  Google Scholar 

  40. Chatterjee S. Review: DPP-4 inhibitors are less effective than metformin for reducing HbA1c in type 2 diabetes. Ann Intern Med 2012;157:JC1–13.

  41. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012;344:e136–9.

    Article  Google Scholar 

  42. Monami M, Ahren B, Dicembrini I, Mannucci E. Dipeptidyl Peptidase-4 Inhibitors And Cardiovascular Risk. Diabetes Obes Metab 2012.

  43. Patil HR, Al Badarin FJ, Al Shami HA et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol 2012;110:826–33.

    Article  CAS  PubMed  Google Scholar 

  44. Gallwitz B, Rosenstock J, Rauch T et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012;380:475–83.

    Article  CAS  PubMed  Google Scholar 

  45. Duckworth WC, Abraira C, Moritz TE et al. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. J Diabetes Complications 2011;25:355–61.

    Article  PubMed  Google Scholar 

  46. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290:2159–67.

  47. Bianchi C, Del PS. Metabolic memory and individual treatment aims in type 2 diabetes–outcome-lessons learned from large clinical trials. Rev Diabet Stud 2011;8:432–40.

    Article  PubMed Central  PubMed  Google Scholar 

  48. Wolffenbuttel BHR. The DCCT: “metabolic control matters”. Diabetes Control and Complications Trial. Neth J Med 1993;43:241–5.

    CAS  PubMed  Google Scholar 

  49. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–89.

    Article  CAS  PubMed  Google Scholar 

  50. Wolffenbuttel BHR, Drossaert CH, Visser AP. Determinants of injecting insulin in elderly patients with type II diabetes mellitus. Patient Educ Couns 1993;22:117–25.

    Article  CAS  PubMed  Google Scholar 

  51. Peyrot M, Rubin RR, Lauritzen T et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673–9.

    Article  PubMed  Google Scholar 

  52. Zafar A, Davies M, Azhar A, Khunti K. Clinical inertia in management of T2DM. Prim Care Diabetes 2010;4:203–7.

    Article  PubMed  Google Scholar 

  53. Avignon A, Attali C, Sultan A, Ferrat E, Le BJ. Clinical inertia: viewpoints of general practitioners and diabetologists. Diabetes Metab 2012;38 Suppl 3:S53–S58.

    PubMed  Google Scholar 

  54. Wolffenbuttel BHR, Aanstoot HJ. Richtlijnen voor Post Authorisatie Studies. Ned Tijdschr Diabetologie 2003;1:55–60.

    Google Scholar 

  55. Gale EA. Post-marketing studies of new insulins: sales or science? BMJ 2012;344:e397–4.

    Article  Google Scholar 

  56. Nayak UA, Govindan J, Baskar V, Kalupahana D, Singh BM. Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM 2010;103:687–94.

    Article  CAS  PubMed  Google Scholar 

  57. Buse JB, Bergenstal RM, Glass LC et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011;154:103–12.

    Article  PubMed  Google Scholar 

  58. Berlie H, Hurren KM, Pinelli NR. Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review. Diabetes Metab Syndr Obes 2012;5:165–74.

    PubMed Central  CAS  PubMed  Google Scholar 

  59. Charbonnel B, Roden M, Urquhart R et al. Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazidebased regimens. Diabetologia 2005;48:553–60.

    Article  CAS  PubMed  Google Scholar 

  60. Harashima K, Hayashi J, Miwa T, Tsunoda T. Long-term pioglitazone therapy improves arterial stiffness in patients with type 2 diabetes mellitus. Metabolism 2009;58:739–45.

    Article  CAS  PubMed  Google Scholar 

  61. Gould M, Sellin JH. Diabetic diarrhea. Curr Gastroenterol Rep 2009;11:354–9.

    Article  PubMed  Google Scholar 

  62. Bouchoucha M, Uzzan B, Cohen R. Metformin and digestive disorders. Diabetes Metab 2011;37:90–6.

    Article  CAS  PubMed  Google Scholar 

  63. Okayasu S, Kitaichi K, Hori A et al. The evaluation of risk factors associated with adverse drug reactions by metformin in type 2 diabetes mellitus. Biol Pharm Bull 2012;35:933–7.

    Article  CAS  PubMed  Google Scholar 

  64. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 2011;154:554–9.

    Article  PubMed  Google Scholar 

  65. Monami M, Vitale V, Lamanna C et al. HbA1c levels and all-cause mortality in type 2 diabetic patients: Epidemiological evidence of the need for personalised therapeutic targets. Nutr Metab Cardiovasc Dis 2012.

  66. Nakar S, Yitzhaki G, Rosenberg R, Vinker S. Transition to insulin in Type 2 diabetes: family physicians’ misconception of patients’ fears contributes to existing barriers. J Diabetes Complications 2007;21:220–6.

    Article  PubMed  Google Scholar 

  67. Saxena R, Elbers CC, Guo Y et al. Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet 2012;90:410–25.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  68. Donnelly LA, Doney AS, Dannfald J et al. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. Pharmacogenet Genomics 2008;18:1021–6.

    Article  CAS  PubMed  Google Scholar 

  69. Donnelly LA, Doney AS, Tavendale R et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther 2011;89:210–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  70. Huang C, Florez JC. Pharmacogenetics in type 2 diabetes: potential implications for clinical practice. Genome Med 2011;3:7–6.

    Article  Google Scholar 

  71. Christensen MM, Brasch-Andersen C, Green H et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics 2011;21:837–50.

    Article  CAS  PubMed  Google Scholar 

  72. Zhou K, Bellenguez C, Spencer CC et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011;43:117–20.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  73. Becker ML, Visser LE, Schaik RH van, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J 2009;9:242–7.

    Article  CAS  PubMed  Google Scholar 

  74. Jendle J, Martin SA, Milicevic Z. Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review. Expert Opin Investig Drugs 2012.

  75. Schauer PR, Kashyap SR, Wolski K et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012;366:1567–76.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  76. Http://www.kinderfonds.nl/centraal/item/over_het_kinderfonds.

Download references

Author information

Authors and Affiliations

  1. Afdeling Interne Geneeskunde, Universiteit van Groningen, 30001, 9700, Groningen, RB, The Netherlands

    B.H.R. Wolffenbuttel

  2. Universitair Medisch Centrum Groningen, Groningen, The Netherlands

    B.H.R. Wolffenbuttel

  3. http://www.bsl.nl

    M.M. van der Klauw

Authors
  1. B.H.R. Wolffenbuttel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M.M. van der Klauw
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B.H.R. Wolffenbuttel.

Additional information

Afdeling Interne Geneeskunde, Universiteit van Groningen, Universitair Medisch Centrum Groningen

Correspondentie:

B.H.R. Wolffenbuttel, internist-endocrinoloog Universiteit van Groningen, Universitair Medisch Centrum Groningen Afdeling Endocrinologie en Stofwisselingsziekten Postbus 30001 9700 RB Groningen

bwo@umcg.nl

twitter: @bhrw

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wolffenbuttel, B., van der Klauw, M. De nieuwe ADA/EASD-consensus type 2 diabetes en wat u daarvan moet weten. NED. TIJDSCHR. DIABET. 10, 206–216 (2012). https://doi.org/10.1007/s12467-012-0152-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12467-012-0152-6

Search

Navigation